v3.21.1
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (26,376) $ (14,911)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 65 47
Stock-based compensation expense 5,565 776
Changes in operating assets and liabilities:    
Prepaid expenses, other assets and right of use assets 703 (1,838)
Accounts payable, accrued expenses, lease liabilities and other liabilities 403 3,769
Net cash used in operating activities (19,640) (12,157)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment and leasehold improvements (316) (16)
Net cash used in investing activities (316) (16)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, net of issuance costs   68,811
Purchase and cancellation of shares from BioXcel Corporation   (9,024)
Exercise of stock options 852 39
Net cash provided by financing activities 852 59,826
Net increase (decrease) in cash and cash equivalents (19,104) 47,653
Cash and cash equivalents, beginning of the period 213,119 32,426
Cash and cash equivalents, end of the period 194,015 80,079
Supplemental cash flow information:    
Interest paid   $ 3
Purchases of equipment and leasehold improvements in accounts payable and accrued expense $ 9  

Source